Stock Ratings / Technology / XLAB / dividends

DUOT (40) GIBO (45) ZENA (54) EXFY (46) ⌘ Pro Terminal →

Exascale Labs Holdings Inc. (Class A) (XLAB) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.15 -0.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.14

Exascale Labs Holdings Inc. (Class A) (XLAB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $202.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.14 (-0.30%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XLAB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY XLAB SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 51 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.97+142.3% Next Q

Q2 (-2Q)

Grade E$2.35+42.6% Next Q

Q3 (-1Q)

Grade E$3.35-6% Next Q

Current

Grade D-$3.15-8.1% Hist 90D α

Trajectory: E (29) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XLAB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XLAB currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Technology with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.06) and Max Pain ($3.31) forces dealer call-delta covering toward $11.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XLAB• $4.8M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XLAB Beats Next Quarterly Revenue & EPS Consensus + Hyperscaler AI CapEx Holds Record Pace”

YES 37%NO 63%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XLAB)

✓Walkthrough of XLAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XLAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.24%▼ DESCENDING CHANNEL

2026-10-30O $3.01H $3.15L $2.82C $3.15VOL 379.1K

RES: $4.45SUP: $0.12SMA50: $3.06SMA200: $8.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XLAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XLAB Butterfly Map → + Track XLAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XLAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XLAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XLAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XLAB)

Technology Rank #590 of 714 ⚔️ DUOT vs XLAB Full Matrix →

1. Head-to-Head Technology Peer Comparison (XLAB vs. DUOT, GIBO, ZENA, EXFY)

Industry: Computer Software: Prepackaged Software (222 Tracked Issuers)

Across 714 tracked Technology securities in the Roarable RQD universe, Exascale Labs Holdings Inc. (Class A) (XLAB) ranks #590 by composite RQD confidence (37/100, grade D-) and #476 by equity capitalization ($202.7M). Within this direct 5-issuer industry benchmark cohort, XLAB leads on earnings valuation at N/A trailing P/E, while DUOT leads on capital efficiency and profitability with -15.9% ROIC and 29.2% gross margin. ZENA currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with XLAB at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XLAB ACTIVE Exascale Labs Holdings Inc. (Class A)	D-	37/100	—	15.8%	-23.7%	-0.63%	$202.7M	Benchmark Subject
DUOT Duos Technologies Group Inc.	D-	40/100	—	29.2%	-15.9%	+0.47%	$203.3M	/duot-vs-xlab →
GIBO GIBO Holdings Limited (Class A)	D	45/100	—	—	-35.0%	+2.42%	$192.2M	/gibo-vs-xlab →
ZENA ZenaTech Inc.	D+	54/100	—	—	—	-0.05%	$185.8M	/zena-vs-xlab →
EXFY Expensify Inc. (Class A)	D	46/100	—	50.3%	-20.4%	-2.41%	$221.6M	/exfy-vs-xlab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0002109869

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Exascale Labs Holdings Inc. (Class A) (XLAB) reported GAAP revenue of $7.0M , GAAP net income of -$7.7M, operating cash flow of -$1.0M, and free cash flow of -$1.0M . On the balance sheet, XLAB closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$7.0M	-$7.7M	-$1.0M	-$1.0M	—	—

3. XLAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XLAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Exascale Labs Holdings Inc. (Class A) (NASDAQ: XLAB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.15 (-0.63% 1D, market cap $202.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 714 tracked Technology issuers, XLAB ranks #590 in composite RQD confidence.

How does XLAB compare to DUOT and GIBO in the Technology sector?

Within the Technology sector (Computer Software: Prepackaged Software), XLAB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 15.8%, and ROIC of -23.7%. By comparison, DUOT (Duos Technologies Group Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -15.9%, cap $203.3M) and GIBO (GIBO Holdings Limited (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $192.2M). Among the 5-stock peer group, XLAB leads on earnings multiple (N/A) while DUOT leads on capital efficiency (-15.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XLAB?

Per XLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0002109869), Exascale Labs Holdings Inc. (Class A) generated $7.0M in revenue, -$7.7M in net income, and -$1.0M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Technology with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XLAB trading relative to its 50-day, 200-day, and 52-week technical levels?

XLAB last traded at $3.15 (-0.63% on volume of 1,251,708 shares), positioning the stock +2.94% above its 50-day simple moving average ($3.06) and -60.77% below its 200-day simple moving average ($8.03). Across its 52-week range of $0.78 to $11.17, XLAB sits at the 22.8% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.76 to $3.54).

XLAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does XLAB pay a dividend and is it safe?

Exascale Labs Holdings Inc. (Class A) (XLAB) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: XLAB RQD Cockpit XLAB 12M Forecast XLAB Earnings & Move XLAB Dividends & DRIP XLAB Insiders & 13F XLAB Whale Options XLAB Profit Sankey XLAB News & Why